Ventas (NYSE:VTR) 주식

Ventas

Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Ventas Inc

VETROPACK HLDF ST PRX A by Vetropack Holding SA

Vitrolife AB

VECTRON SYSTEMS AG NEW by Vectron Systems AG New

Vectron Systems AG

Viatris Inc

VECTOR INC TOKYO by Vector Inc.

Vitru Ltd

JP Morgan analyst Michael Mueller maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Neutral and raises the price target from $71 to $73.

News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Ventas, Raises Price Target to $73

WIIM

CBRE

EQIX

WELL

WHLR

Shares of REIT and utility stocks are trading lower amid overall market weakness. Rising Treasury yields may be driving a rotation out of income-paying sectors.

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 14.65% since its last report. The company recently reported that it has 10.96 million shares sold short, which is 3.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741113038_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Ventas Gaining or Losing Market Support?

RBC Capital analyst Michael Carroll maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $70 to $74.

RBC Capital Maintains Outperform on Ventas, Raises Price Target to $74

In the last three months, 5 analysts have published ratings on Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.2, a high estimate of $78.00, and a low estimate of $65.00. Surpassing the previous average price target of $67.80, the current average has increased by 2.06%.
<img src="https://www.benzinga.com/files/images/story/2025/1739556051_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Ventas among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ventas's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ventas's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Get to Know Ventas Better</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Ventas: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Ventas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.52%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.2%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.08%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.42, Ventas adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Ventas: What You Need To Know

Wedbush analyst Richard Anderson maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $69 to $78.

Wedbush Maintains Outperform on Ventas, Raises Price Target to $78

General

Ventas shares are trading higher after the company reported better-than-expected Q4 financial results.

Guidance

Ventas Sees FY25 Normalized FFO Per Share Midpoint $3.41

Earnings

Earnings Beats

Ventas Q4 2024 FFO $0.81 Beats $0.80 Estimate, Sales $1.287B Beat $1.262B Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Ratings for Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $67.0, a high estimate of $69.00, and a low estimate of $65.00. This current average has decreased by 0.74% from the previous average price target of $67.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738004441_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ventas by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ventas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ventas's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>All You Need to Know About Ventas</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Financial Insights: Ventas</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Ventas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.52%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Ventas's net margin excels beyond industry benchmarks, reaching 1.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ventas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ventas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ventas's debt-to-equity ratio is below the industry average at 1.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Ventas Stock

Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Sector Perform and raises the price target from $68 to $69.

Scotiabank Maintains Sector Perform on Ventas, Raises Price Target to $69

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 48.99% since its last report. The company recently reported that it has 10.98 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737658813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Ventas?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst David Rodgers upgraded the rating for Ventas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Neutral to Outperform but lowered the price target from $66 to $65. Ventas shares closed at $58.36 on Thursday. <a href="https://www.benzinga.com/quote/VTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst James Faucette upgraded Clearwater Analytics Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Equal-Weight to Overweight and raised the price target from $30 to $34. Clearwater Analytics shares closed at $27.09 on Thursday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Tom O&#8217;Malley upgraded Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from Underweight to Overweight and raised the price target from $80 to $125. Lumentum shares closed at $89.36 on Thursday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Fatima Boolani upgraded the rating for Cloudflare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Neutral to Buy and raised the price target from $95 to $145. Cloudflare shares closed at $114.82 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Andrew Didora upgraded American Airlines Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) from Underperform to Neutral and raised the price target from $12 to $20. American Airlines shares closed at $18.29 on Thursday. <a href="https://www.benzinga.com/quote/AAL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-1024x603.png" alt="" class="wp-image-739021" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Upgrades

Pre-Market Outlook

Markets

CWAN

LITE

This American Airlines Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Baird analyst David Rodgers upgrades Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Neutral to Outperform and lowers the price target from $66 to $65.

Baird Upgrades Ventas to Outperform, Lowers Price Target to $65

Baird analyst David Rodgers maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Neutral and raises the price target from $65 to $66.

Baird Maintains Neutral on Ventas, Raises Price Target to $66

Following this successful lease amendment, the completed closing of the 11 community International JV / Welltower Portfolio, and the expected closings of the remaining previously-announced acquisition of 30 communities
<ul>
<li>Following this successful lease amendment, the completed closing of the 11 community International JV / Welltower Portfolio, and the expected closings of the remaining previously-announced acquisition of 30 communities from two additional currently leased portfolios, the Company has largely cleared its lease maturities through 2029. After giving effect to these transactions, Brookdale will own over 75% of its consolidated units, marking another significant step in the Company's efforts to increase its owned real estate portfolio, benefiting from the economics of ownership, while substantially improving the cash flow profile and reducing risk associated with its overall leased portfolio.</li>
<li>The Company expects the Ventas lease amendment to provide a $15+ million improvement to the Company's 2025 cash flows.(1) Beginning in 2026, the Company expects additional cash flow improvement, including continued operating income growth, the benefit of continued appropriate expense management relative to the Company's portfolio size, partially offset by incremental rent expense.</li>
</ul>

Health Care

Brookdale Senior Living Has Entered Into Mutually Beneficial Agreements With Ventas To Amend Its Triple-Net Master Lease Arrangement, Which Can Potentially Provide Over $15M Improvement To The Company's 2025 Cash Flows

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has risen 161.6% since its last report. The company recently reported that it has 21.48 million shares sold short, which is 6.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733770823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 6.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Ventas's Recent Short Interest

Throughout the last three months, 5 analysts have evaluated Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ventas and provided 12-month price targets. The average target is $69.0, accompanied by a high estimate of $71.00 and a low estimate of $65.00. Witnessing a positive shift, the current average has risen by 8.15% from the previous average price target of $63.80.
<img src="https://www.benzinga.com/files/images/story/2024/1733407325_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ventas among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ventas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Ventas's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Get to Know Ventas Better</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Financial Milestones: Ventas's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Ventas's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 7.52%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin excels beyond industry benchmarks, reaching 1.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ventas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ventas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Ventas Stands With Analysts

Mizuho analyst Vikram Malhorta maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and lowers the price target from $71 to $68.

Mizuho Maintains Outperform on Ventas, Lowers Price Target to $68

Press Releases

Ventas Announces Pricing of an Underwritten Offering of 10.6 Million Shares of Common Stock

Ventas to Participate in Investor Meetings at Nareit's REITworld 2024 Annual Conference

Ventas Earns Nareit 2024 Healthcare "Leader in the Light" Award

Ventas Comments on Master Lease with Brookdale Senior Living

Ventas Declares Fourth Quarter 2024 Dividend of $0.45 Per Common Share

Ventas Reaches Mutually Beneficial Agreements with Brookdale Senior Living

Ventas Announces Fourth Quarter 2024 Earnings Release Date and Conference Call

Ventas Announces Tax Treatment Of 2024 Distributions

Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend

Ventas to Participate in Investor Meetings at Citi 2025 Global Property CEO Conference

Comments

Ventas

뉴스

파트너 / 기고자

벤징가 글로벌